Regeneron Pharmaceuticals Inc

$ 372.83
Updated 09:35:41
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 529,505
High $ 389.20
Low $ 370.35
Open $ 379.28
Prev close $ 381.69
# of shares 106.32M
Market cap 39,640M USD

Market closed
Regeneron Pharmaceuticals Inc
Market is closed, opens at 14:30
Price development Latest 1 week 1 month 3 months 6 months 1 year
  372.83 -2.6% Stock price decreasing 4.5% Stock price increasing -5.6% Stock price decreasing 21.0% Stock price increasing -2.1% Stock price decreasing
Powered by TradingView

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
10 December 2018 11:43:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB3 - 2018-12-10 12:43:54 - 2018-12-10 11:43:54 - 1000 - Website: OKAY